<DOC>
	<DOCNO>NCT01298492</DOCNO>
	<brief_summary>This study provide open-label drug eligible patient complete prior study PF-00547659 . The primary endpoint study long-term safety .</brief_summary>
	<brief_title>A Study To Monitor Long-Term Treatment With PF-00547659</brief_title>
	<detailed_description>The rationale conduct open-label extension ( OLE ) study primarily evaluate long term safety PF 00547659 . This protocol also provide opportunity continue treatment subject respond treatment feeder study . It also provide opportunity initial treatment subject randomize placebo feeder study . This multi center Phase 2 , open label , safety extension study feeder study evaluate PF 00546759 subject moderate severe Crohn 's disease . Subjects eligible study complete 12 week double blind induction period study A7281006 stratify responder non responder base change CDAI study , without unblinding treatment assignment study A7281006 . Additionally , subject complete study A7281008 clinical response , define protocol , also eligible study treat `` responder '' . All subject enter study must discontinue immunosuppressant therapy . Subjects enter study give 75 mg SC dose baseline every 4 week Week 72 . After active treatment period , subject enter 24 month follow period include 6 monthly visit follow 18 month extend contact ( every 6 month telephone contact ) . At Week 96 , subject undergo End Study visit continue every 6 month telephone contact Week 168 .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects 18 76 year age . Subjects previously enrol study A7281006 complete blind 84 day ( 12 week ) induction period study A7281008 complete Week 12 demonstrate clinical response define protocol . Subjects complete Day 84 ( Week 12 ) PF00547659 study experience serious event ( ) relate investigational product , unstable medical condition , reason , opinion investigator , would hinder entry participation study . Subjects take dose azathioprine , 6mercaptopurine methotrexate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Anti-TNF Refractory</keyword>
	<keyword>Immunosuppressant Refractory</keyword>
	<keyword>Active Crohn 's disease</keyword>
</DOC>